查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1917800

照护现场基因检测市场－2026-2031年预测

Point-Of-Care Genetic Testing Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2025 年，照护现场(POC) 基因检测市场规模将达到 19.37 亿美元，到 2031 年将达到 26.78 亿美元，复合年增长率为 5.55%。

照护现场基因检测（POC​​ GT）市场是诊断和精准医疗领域一个变革性且快速成长的细分市场。其特点是在非集中式实验室环境下进行基因分析，并在临床相关的时限内，于患者所在位置或附近提供可操作的检测结果。这种由可携式整合平台实现的去中心化模式，透过大幅缩短检测週期、简化检测流程以及将基因数据直接整合到即时临床决策中，从根本上改变了基因诊断的范式。

主要市场驱动因素和临床需求

推动市场成长的关键因素之一是医疗模式转向个人化和精准医疗的加速。随着治疗策略越来越依赖个体的基因谱，快速且方便的基因分型变得至关重要。即时基因检测（POC​​基因检测）满足了这一需求，使医生能够在诊疗现场根据数据做出药物选择、剂量调整和治疗方法分层等决策。这种能力在肿瘤学、药物基因组学和感染疾病等领域尤其重要，因为及时获得的基因资讯直接影响治疗效果和患者预后。

另一个并行的驱动力是照护现场平臺本身的技术革新。微流体、生物感测器和分子诊断技术的进步融合，催生出既精密又易于使用的系统，能够在分散式环境下执行复杂的基因分析，包括PCR、等温扩增和靶向定序。这些系统将样本製备、扩增和检测整合到基于晶片的自动化工作流程中，最大限度地减少了人工操作时间和所需的专业技术。这种技术革新正将即时基因检测从简单的检测概念转变为能够检测多种具有重要临床意义的基因标记的方法。

此外，临床医生和患者对遗传学在健康和疾病中作用的认识不断提高，也带来了持续的需求。大众对遗传疾病的了解日益加深，加之医师在基因组医学方面的教育不断进步，正推动人们积极进行风险评估、早期诊断和计划生育的检测。即时检测（POC​​检测）的固有优势——便捷、快速、减少患者随访需求——与这一趋势完美契合，促进了检测的普及和融入日常诊疗实践，尤其是在基层医疗和急诊护理机构。

战略优势与价值提案

即时基因检测的核心提案在于其快速出具结果和及时决策的能力。透过消除检体运输和中心检查室批量处理带来的物流延误，诊断时间从数天或数週缩短至数分钟或数小时。这种速度使得临床能够即时采取应对措施，例如启动标靶治疗、调整药物和实施感染控制措施，从而显着改善病患管理、提高医院工作流程效率并降低整体医疗成本。在患者就诊时获取基因资讯也有助于提高医疗服务的连续性和患者满意度。

区域市场动态

北美已确立其领先的区域市场地位，凭藉其先进的医疗基础设施、精准医疗的高普及率、优惠的报销机制以及对诊断创新的大量投资，保持着这一主导地位。主要平台开发商的存在和强大的生物技术产业进一步巩固了其主导地位。然而，该市场正经历全球扩张。欧洲和亚太等地区正经历着加速成长，这得益于医疗现代化程度的提高、遗传疾病盛行率的上升以及对分散式医疗模式投资的增加，表明即时基因检测（POC​​ GT）解决方案的地域部署范围正在扩大。

竞争格局与平台演进

竞争格局主要由成熟的诊断公司和专业的分子诊断公司所构成。主要企业在检测专案广度、分析效能、易用性、速度以及与数位健康生态系统的连结性等方面竞争。市场以完全整合的盒式系统为主导，这些系统在感染疾病占据主导地位，并正日益渗透到肿瘤学和药物基因组学应用领域。策略重点在于扩展检测范围以涵盖更多基因标靶，提升多重检测能力，并确保平台在各种资源环境下可靠运作。展现明确的临床效用、成本效益以及与各种临床工作流程的无缝整合是成功的关键。

挑战与未来前景

市场成长面临许多挑战，包括需要对分散式检查进行严格的监管检验、确保非实验室环境下的品管一致性，以及解决新型即时检测（POC​​）的报销政策问题。此外，平台和试剂盒的初始成本在成本敏感环境中也可能成为推广应用的障碍。

然而，长远发展方向无疑是扩展和完善。未来的成长将由技术的持续小型化、针对慢性病和肿瘤的新型生物标记组合的开发以及人工智慧在结果解读中的应用所驱动。即时基因检测与远端医疗和数位健康记录的融合将进一步巩固其在构建诊断和治疗之间持续、数据驱动的闭环中的作用。

总之，照护现场基因检测市场正处于迈向即时、可操作的基因组分析的关键转折点。其发展与精准医疗的进步和诊断能力的去中心化密不可分。对业内专家而言，策略挑战在于开发一个强大的、符合CLIA豁免标准的平台，并扩展其临床应用范围；产生可靠的卫生经济学证据；以及建立获得监管部门核准和报销的途径。未来，即时基因检测将成为贯穿整个医疗保健流程的综合工具，从根本上提高医疗干预的速度和个人化程度。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章 依类型照护现场基因检测市场

  • 介绍
  • 聚合酵素链锁反应（PCR）
  • 等温扩增
  • 其他的

第六章 依应用照护现场基因检测市场

  • 介绍
  • 感染疾病
  • 癌症筛检
  • 个人化医疗
  • 其他的

第七章照护现场基因检测市场

  • 介绍
  • 医院
  • 专科诊所
  • 其他的

第八章 按地区照护现场基因检测市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十章：公司简介

  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Qiagen NV
  • Bio-Rad Laboratories, Inc.
  • Becton Dickinson
  • Danaher Corporation
  • bioMerieux
  • Siemens Healthineers AG
  • OraSure Technologies Inc

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615777

Point-Of-Care Genetic Testing Market, with a 5.55% CAGR, is expected to grow to USD 2.678 billion in 2031 from USD 1.937 billion in 2025.

The point-of-care genetic testing (POC GT) market is a transformative and rapidly expanding segment within the diagnostics and precision medicine landscape. It is defined by the execution of genetic analyses outside of centralized laboratory settings, providing actionable results at or near the patient location within a clinically relevant timeframe. This decentralization, enabled by portable and integrated platforms, is fundamentally altering the paradigm of genetic diagnostics by dramatically reducing turnaround times, simplifying testing workflows, and integrating genetic data directly into immediate clinical decision-making.

Core Market Drivers and Clinical Imperatives

The primary catalyst for market growth is the accelerating transition toward personalized and precision medicine. As therapeutic strategies become increasingly tailored to an individual's genetic profile, the need for rapid, accessible genotyping has become paramount. POC genetic testing fulfills this need by enabling clinicians to make data-driven decisions on drug selection, dosing, and therapy stratification at the point of clinical interaction. This capability is critical in fields like oncology, pharmacogenomics, and infectious disease, where timely genetic information directly impacts treatment efficacy and patient outcomes.

A concurrent driver is the expanding technical capabilities of point-of-care platforms themselves. Advances in microfluidics, biosensors, and molecular diagnostics have converged to create sophisticated, yet user-friendly, systems capable of performing complex genetic analyses-such as PCR, isothermal amplification, and targeted sequencing-in decentralized settings. These systems integrate sample preparation, amplification, and detection into automated, cartridge-based workflows, minimizing hands-on time and technical expertise required. This technological evolution is transforming POC GT from a concept for simple tests into a viable modality for a broadening range of clinically significant genetic markers.

Furthermore, growing clinical and patient awareness of the role of genetics in health and disease is creating sustained demand. Increased public understanding of hereditary conditions, coupled with physician education on genomic medicine, is driving proactive testing for risk assessment, early diagnosis, and family planning. The inherent advantages of POC testing-convenience, speed, and reduced need for patient follow-up-align perfectly with this trend, facilitating higher testing uptake and integration into routine care pathways, particularly in primary and acute care settings.

Strategic Advantages and Value Proposition

The definitive value proposition of POC genetic testing lies in its capacity for rapid results and timely decision-making. By eliminating the logistical delays associated with sample transport and batch processing in core labs, it compresses the diagnostic timeline from days or weeks to minutes or hours. This acceleration enables immediate clinical actions, such as initiating targeted therapy, adjusting medication, or implementing infection control measures, which can significantly improve patient management, streamline hospital workflows, and reduce overall healthcare costs. The ability to obtain genetic information during a single patient visit also enhances care continuity and patient satisfaction.

Geographic Market Dynamics

North America is established as the leading regional market, a position sustained by a synergistic combination of advanced healthcare infrastructure, high adoption of precision medicine, favorable reimbursement frameworks, and significant investment in diagnostic innovation. The presence of major platform developers and a robust biotech sector further consolidates this leadership. However, the market is experiencing global expansion. Regions such as Europe and Asia-Pacific are witnessing accelerated growth driven by increasing healthcare modernization, rising prevalence of genetic disorders, and growing investment in decentralized care models, indicating a broadening geographic footprint for POC GT solutions.

Competitive Landscape and Platform Evolution

The competitive environment is characterized by established diagnostic corporations and specialized molecular companies. Leaders compete on the basis of test menu breadth, analytical performance, ease of use, speed, and connectivity within digital health ecosystems. The market features fully integrated, cartridge-based systems that dominate the infectious disease segment and are increasingly penetrating oncology and pharmacogenomic applications. Strategic focus is on expanding test panels to cover more genetic targets, improving multiplexing capabilities, and ensuring platforms can operate reliably in varied resource settings. Success depends on demonstrating clear clinical utility, cost-effectiveness, and seamless integration into diverse clinical workflows.

Challenges and Future Trajectory

Market growth faces challenges, including the need for stringent regulatory validation of decentralized tests, ensuring consistent quality control outside the lab environment, and navigating reimbursement policies for novel POC assays. The initial cost of platforms and cartridges can also be a barrier to widespread adoption in cost-sensitive settings.

Nevertheless, the long-term trajectory is unequivocally toward expansion and sophistication. Future growth will be driven by the continuous miniaturization of technology, the development of new biomarker panels for chronic disease and oncology, and the integration of artificial intelligence for result interpretation. The convergence of POC genetic testing with telehealth and digital health records will further solidify its role in creating a continuous, data-driven loop between diagnosis and treatment.

In conclusion, the point-of-care genetic testing market represents a pivotal shift toward immediate, actionable genomics. Its evolution is inextricably linked to the advancement of precision medicine and the decentralization of diagnostic capabilities. For industry experts, the strategic imperative lies in developing robust, CLIA-waived platforms with expanding clinical menus, generating robust health-economic evidence, and navigating the pathway to regulatory approval and reimbursement. The future points toward POC genetic testing becoming an embedded tool across the care continuum, fundamentally enhancing the speed and personalization of medical intervention.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Point-of-Care Genetic Testing Market Segmentation

  • By Type
  • Polymerase Chain Reaction (PCR)
  • Isothermal Amplification
  • Others
  • By Application
  • Infectious Disease
  • Cancer Screening
  • Personalized Medicine
  • Others
  • By End-User
  • Hospitals
  • Specialized Clinics
  • Others
  • By Geography
  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. POINT-OF-CARE GENETIC TESTING MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Polymerase Chain Reaction (PCR)
  • 5.3. Isothermal Amplification
  • 5.4. Others

6. POINT-OF-CARE GENETIC TESTING MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Infectious Disease
  • 6.3. Cancer Screening
  • 6.4. Personalized Medicine
  • 6.5. Others

7. POINT-OF-CARE GENETIC TESTING MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Specialized Clinics
  • 7.4. Others

8. POINT-OF-CARE GENETIC TESTING MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Abbott
  • 10.2. F. Hoffmann-La Roche Ltd
  • 10.3. Thermo Fisher Scientific Inc.
  • 10.4. Qiagen N.V.
  • 10.5. Bio-Rad Laboratories, Inc.
  • 10.6. Becton Dickinson
  • 10.7. Danaher Corporation
  • 10.8. bioMerieux
  • 10.9. Siemens Healthineers AG
  • 10.10. OraSure Technologies Inc

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations